

Prof. Dr. rer. Nat. Peter Buckel

Senior Life Science Professional with over 40 years experience in Biotech and Healthcare Industry

Advisory and Expert functions (1996 – ongoing)

- Consulting several start-up and early stage companies (ongoing)
- Expert opinion for venture capital and patent offices (ongoing)
- More than 20 board memberships in Germany, Switzerland, Spain, Italy, USA, Japan and Singapore (ongoing)
- Expert reviewer of the Austrian translational funding Program FFG (since 2006, ongoing) and of the “Bayerische Therapiestrategie Covid19 (2021-2024)”, several BMBF advisory group memberships
- Advisory industry lectures in China and Korea
- Member of scientific advisory groups in Ireland and Singapore (leading to more than 2.5 bn USD investment)

Biotech Industry (1999 – 2013)

SuppreMol GmbH, Munich; Co-founder and CEO (2005 - 2013)

- Development of an immune regulating protein from early research to proof of concept in clinical phase II (Thrombocytopenia and Lupus); exit by selling the Company to Baxter for 200 m€

Atugen AG, Berlin; CEO (2004 – 2005)

- Development of a proprietary RNAi technology into clinical studies; reverse merger by integrating the Company into an AIM listed „shell company“, now called Silence Therapeutics

Xantos Biomedicine GmbH, Munich; Co-founder and CEO (1999 – 2003)

- Target discovery company with a high-throughput technology platform

Pharma and Diagnostic Industry (1977 – 1999)

Roche Diagnostics GmbH, Penzberg (1997 – 1999)

- SVP Molecular Medicine, starting and managing gene- and cell therapy companies in Hannover, Milano and San Diego (Cytonet, MolMed, Molecular Medicine); first concepts of personalized medicine after integration of Boehringer Mannheim into Roche

Boehringer Mannheim GmbH (1977 – 1997)

- Started as Senior Scientist Genetics, took over department responsibilities of Microbiology, Biochemistry and Pharma Biologics; finally responsible for Global Pharma Research and Biologics Production as SVP and Member of the Executive Board; major focus: Recombinant expression and engineering of diagnostic enzymes; start of Pharma Biologics product pipeline with Reteplase (recombinant plasminogen activator), Erythropoietin and antibodies

Academic background

- Honorary Professor LMU Munich, Dep. Microbiology (since 1995)
- Lectureship LMU Munich „Applied Biotechnology“ (1988 – 2011)
- Postdoctoral Fellow: Uni Regensburg (Akad. Rat), Inst. Physiol. Chem. Munich (H-G Zachau) and MPI Mol. Genet. Berlin (H-G Wittmann) (1975 – 1977)
- Dr. rer. nat. in Microbiology, University Regensburg (1972 – 1975)
- Diploma in Microbiology, LMU Munich (1971)

Additional academic functions

- Advisory Board of „Deutsche Stiftung für Impfstoff-Forschung“ VPM (2003 – 2009, Chairman since 2005)
- Chairman of the Sci. Advis. Board of the German Human Genome Project (1998-2003)
- Chairman of the „Kuratorium der Max-Planck-Institute für Biochemie und Neurobiologie“, Munich (2000-2004), member of the board of trustees (since 1996)
- President of the German microbiology association VAAM (1995-1997)
- Founding member of the European Academy of Science and Art (EASA), (since 1990); active in Class II (Medicine and Science)
- Mentoring program at the LMU, Mentor Circle BioM and Innovation Mentor at the MPG (Max Planck Innovation)

Selected Skills

- Pharma R&D (oncology, cardiovascular, immunology), Biologics. Innovation management, risk management, self-motivating learning organization, start-up companies, managing and financing biotech companies (raised more than 100 m€), reverse merger (Stock Market), M&A.
- Peter is author and co-author of 64 scientific publications, 4 book contributions (2 as editor) and 58 patents.